Skip to main content
. 2016 Apr 20;18(6):485–493. doi: 10.1016/j.hpb.2016.03.001

Table 1.

Brief summary of included studies

Study Study period Regimen Treatment N Follow-up regimen after treatment Recurrence Trial name
Primrose 2014 Feb 2007–Nov 2012 Perioperativea FOLFOX/Surgery/FOLFOXe vs. FOLFOXe+CET/Surgery/FOLFOXe+CET 257 CT or MRI every 3 months for 2 years, then every 6 months for 3 years, until progression or death Disease progression established by MDT New EPOC
Nordlinger 2013 Oct 2000–July 2004 Perioperativeb Surgery vs. FOLFOX/Surgery/FOLFOX 364 CXR, abdominal USS or CT, and CEA every 3 months for 2 years, then every 6 months thereafter Imaging, cytology or histology EPOC/
EORTC 40983
Ychou 2009 Dec 2001–July 2006 Adjuvantc Surgery/FUFA vs. Surgery/FOLFORI 306 Physical, haematological and biochemical evaluation, CEA and CT every 3 months for 2 years, then every 6 months for 2 years NR –
Portier 2006 Dec 1991–Dec 2001 Adjuvantd Surgery vs. Surgery/FUFA 171 Clinical examination, abdominal USS, CXR, CEA, ±CT every 3 months for 2 years, then yearly until death or end of study NR FFCD ACHBTH AURC 9002

Abbreviations: CET, cetuximab; 5-FU, 5-fluorouracil; FUFA, folinic acid and 5-FU; FOLFORI, folinic acid, 5-FU and irinotecan; FOLFOX, folinic acid, 5-FU and oxaliplatin; CT, computed tomography scan; MRI, magnetic resonance imaging; USS, ultrasound scan; CEA, carcinoembryonic antigen; MDT, multidisciplinary team; NR, not reported; EORTC, European Organisation for Research and Treatment of Cancer; EPOC, the Cochrane Effective Practice and Organization of Care Group: FFCD, Fédération Francophone de Carcinologie Digestive.

a

4–6 Cycles over 12 weeks pre-operatively with a minimum break of 4 weeks prior to surgery and 4–6 cycles over 12 weeks post-operatively.

b

Six 14-day cycles pre-operatively with liver resection performed 2–5 weeks after the last administration of preoperative chemotherapy, and six 14-day cycles post-operatively.

c

Twelve cycles over 6 months.

d

Six cycles over 6 months.

e

Three alternative regimens were allowed. Regime 1, oxaliplatin and fluorouracil (n = 156); regimen 2, oxaliplatin and oral capecitabine (n = 51); regimen 3, patients who had received adjuvant oxaliplatin could receive irinotecan with fluorouracil instead of oxaliplatin (n = 26).